Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study
暂无分享,去创建一个
Christer Halldin | Lars Farde | Ikuo Odano | Hans Olsson | Aurelija Jucaite | Stefan Pauli | C. Halldin | L. Farde | A. Jucaite | S. Pauli | I. Odano | H. Olsson
[1] C Crouzel,et al. Quantification of Benzodiazepine Receptors in Human Brain Using PET, [11C]Flumazenil, and a Single-Experiment Protocol , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[2] K. B. Larson,et al. Strategies for in vivo Measurement of Receptor Binding Using Positron Emission Tomography , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[3] R. Baldessarini,et al. Synthesis and biological evaluation of a series of novel N- or O-fluoroalkyl derivatives of tropane: potential positron emission tomography (PET) imaging agents for the dopamine transporter. , 2001, Bioorganic & medicinal chemistry letters.
[4] H. N. Wagner,et al. Multicompartmental Analysis of [11C]-Carfentanil Binding to Opiate Receptors in Humans Measured by Positron Emission Tomography , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[5] L. Farde,et al. Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium Analysis , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[6] M E Phelps,et al. Neuroreceptor Assay with Positron Emission Tomography: Equilibrium versus Dynamic Approaches , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[7] D Guilloteau,et al. Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4'-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3',4'-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. , 1997, Journal of medicinal chemistry.
[8] A. Toga. Three-dimensional neuroimaging , 1990 .
[9] Deborah C Mash,et al. Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT‐PCR , 2003, The European journal of neuroscience.
[10] C. Halldin,et al. Brain radioligands--state of the art and new trends. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[11] Mark Slifstein,et al. Positron emission tomography: imaging and quantification of neurotransporter availability. , 2002, Methods.
[12] A. Fischman,et al. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain , 1998, Synapse.
[13] J. Swanson,et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: Therapeutic implications , 2002, Synapse.
[14] D J Brooks,et al. Comparison of Methods for Analysis of Clinical [11C]Raclopride Studies , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[15] F. Fazio,et al. The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT , 2001, Neurological Sciences.
[16] G. Schwarz. Estimating the Dimension of a Model , 1978 .
[17] A. Gjedde,et al. Quantification of Neuroreceptors in the Living Human Brain. I. Irreversible Binding of Ligands , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[18] G. Sedvall,et al. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. , 1986, Science.
[19] M. Phelps,et al. Effects of Temporal Sampling, Glucose Metabolic Rates, and Disruptions of the Blood—Brain Barrier on the FDG Model with and without a Vascular Compartment: Studies in Human Brain Tumors with PET , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[20] T. Greitz,et al. Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. , 1981, Journal of computer assisted tomography.
[21] M. Grégoire,et al. Anatomic and Biochemical Correlates of the Dopamine Transporter Ligand 11C-PE2I in Normal and Parkinsonian Primates: Comparison with 6-[18F]Fluoro-L-Dopa , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[22] C. Bohm,et al. Automated blood sampling systems for positron emission tomography , 1988 .
[23] K. Tatsch,et al. Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment , 2000, European Journal of Nuclear Medicine.
[24] D E Kuhl,et al. Compartmental Analysis of [11C]Flumazenil Kinetics for the Estimation of Ligand Transport Rate and Receptor Distribution Using Positron Emission Tomography , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[25] D. Guilloteau,et al. Visualization of the Dopamine Transporter in the Human Brain Postmortem with the New Selective Ligand [125I]PE2I , 1999, NeuroImage.
[26] H. Akaike. A new look at the statistical model identification , 1974 .
[27] Christer Halldin,et al. [18F]β-CIT-FP is superior to [11C]β-CIT-FP for quantitation of the dopamine transporter , 1997 .
[28] Christer Halldin,et al. Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET , 2004, NeuroImage.
[29] Pat Hanrahan,et al. Volume Rendering , 2020, Definitions.
[30] C. Halldin,et al. Variability in D2‐dopamine receptor density and affinity: A PET study with [11C]raclopride in man , 1995, Synapse.
[31] M Slifstein,et al. Effects of statistical noise on graphic analysis of PET neuroreceptor studies. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] N. Zahniser,et al. Rapid regulation of dopamine transporter function by substrates, blockers and presynaptic receptor ligands. , 2003, European journal of pharmacology.
[33] J. Tiihonen,et al. Measurement of the Striatal Dopamine Transporter Density and Heterogeneity in Type 1 Alcoholics Using Human Whole Hemisphere Autoradiography , 2001, NeuroImage.
[34] D. Guilloteau,et al. Synthesis and Ligand Binding of Nortropane Derivatives: N‐Substituted 2β‐Carbomethoxy‐3β‐(4′‐iodophenyl)nortropane and N‐(3‐ Iodoprop‐(2E)‐enyl)‐2β‐carbomethoxy‐3β‐(3′,4′‐disubstituted phenyl)nortropane. New High‐Affinity and Selective Compounds for the Dopamine Transporter. , 1997 .
[35] S. Haber,et al. Immunocytochemical localization of the dopamine transporter in human brain , 1999, The Journal of comparative neurology.
[36] Quantification of [123I]PE2I binding to dopamine transporters with SPET , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[37] Yuan-Hwa Chou,et al. [11C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[38] M. Mintun,et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.
[39] G. Sedvall,et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. , 1997, Brain : a journal of neurology.
[40] David J. Schlyer,et al. Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[41] C. Halldin,et al. Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[42] G. Sedvall,et al. Evaluation of SCH 39166 as PET ligand for central D1 dopamine receptor binding and occupancy in man , 1995, Psychopharmacology.
[43] Christer Halldin,et al. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: Association between striatal dopamine markers and motor hyperactivity , 2005, Biological Psychiatry.
[44] C. Halldin,et al. Quantification of [11C]FLB 457 Binding to Extrastriatal Dopamine Receptors in the Human Brain , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[45] Merja Haaparanta,et al. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia , 2001, Schizophrenia Research.
[46] R. Moore. Organization of midbrain dopamine systems and the pathophysiology of Parkinson's disease. , 2003, Parkinsonism & related disorders.
[47] A. Lammertsma,et al. Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.
[48] K Wienhard,et al. The ECAT EXACT HR: Performance of a New High Resolution Positron Scanner , 1994, Journal of computer assisted tomography.